The Effect of Three Cyclo-oxygenase Inhibitors on Intensity of Primary Dysmenorrheic Pain
article
OA: closed
CC0
Abstract
OBJECTIVE: To determine the effect of 3 different cyclo-oxygenase (COX) inhibitors on primary dysmenorrheic pain. METHOD: Eleven female patients self-medicated with either placebo (sugar), 25 mg of the COX-2 specific inhibitor rofecoxib, 50 mg of the nonselective COX inhibitor diclofenac potassium, or 7.5 mg of the COX-2 selective inhibitor meloxicam, over 4 menstrual cycles. Pain was assessed using the McGill Pain Questionnaire and a visual analog scale. RESULTS: The pain response index, present pain index, and visual analog scale were highly correlated as measures of intensity of pain (r=0.81 to 0.96, P<0.0001). Rofecoxib and diclofenac potassium both decreased the duration of dysmenorrheic pain compared with placebo (P<0.001) and with meloxicam (P<0.01), and were equally effective in improving pain, compared with placebo, after each capsule (P<0.001). When compared with placebo, both drugs also provided 50% or more pain relief, after each capsule (P<0.0048). Meloxicam, although superior to placebo, was not as effective as rofecoxib and diclofenac potassium in reducing pain, and when compared with placebo, was associated with providing 50% or more of pain relief only after the third and fourth capsules (P=0.016). CONCLUSIONS: Rofecoxib and diclofenac potassium, when taken in recommended doses, were equally effective in alleviating pain associated with primary dysmenorrhea.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (19)
- Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data via openalex
- doi:10.1016/s0029-7844(99)00360-9 via openalex
- doi:10.1016/s0029-7844(01)01522-8 via openalex
- doi:10.1073/pnas.96.13.7563 via openalex
- doi:10.1007/pl00022377 via openalex
- doi:10.1016/0197-0070(88)90036-8 via openalex
- doi:10.1016/j.jpag.2004.01.002 via openalex
- doi:10.1002/14651858.cd001751 via openalex
- doi:10.1124/jpet.300.2.367 via openalex
- doi:10.1016/0304-3959(75)90044-5 via openalex
- doi:10.1097/00006250-200110000-00007 via openalex
- doi:10.1016/0028-2243(81)90076-9 via openalex
- doi:10.1016/0002-9343(86)90083-5 via openalex
- doi:10.1016/s0304-3959(97)00005-5 via openalex
- W6629231293 via openalex
- W6648932199 via openalex
- W6822942958 via openalex
- doi:10.1126/science.294.5548.1871 via openalex
- doi:10.1016/s0885-3924(02)00628-0 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:14:16.517584+00:00
License: CC0
· commercial use OK